SJ

Saurabh Juneja

Active Director Director DIN 06545637
DIN 06545637 First appointment May 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since May 2013
Shareholding value •••• Premium profile

About Saurabh Juneja

Data last updated:

Saurabh Juneja is a Director at Farlex Pharmaceuticals Private Limited (since 2019), Director at Kesar Drugs Private Limited (since 2022) and Director at Oxermed Labs Private Limited (since 2021), and holds 2 more current directorships. The companies operate in Pharma. The 3 current companies with reported revenue have a combined latest revenue of ₹16.81 Cr; the largest is Farlex Pharmaceuticals Private Limited at ₹15.67 Cr (FY 2025). Earlier, Saurabh Juneja was a Director at Krishna Intercontinental Private Limited (from 2013).

DIN 06545637
Primary Designation Director
Industry Pharma
First Appointment 30 May 2013
Oldest Company Age 13 yrs
Largest company Farlex Pharmaceuticals Private Limited · ₹15.67 Cr (FY 2025)
Combined revenue ₹16.81 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 Nov 20192014₹15.67 Cr (FY 2025)Active
Kesar Drugs Private Limited U24290HR2022PTC103991
Director10 Oct 20222022₹70.9 Lakh (FY 2025)Active
Oxermed Labs Private Limited U24299HR2021PTC094810
Director03 May 20212021₹42.7 Lakh (FY 2024)Active
Kesar Aerosols Private Limited U21000HR2026PTC149752
Director25 Aug 20262026Active
Farlex Lifesciences Private Limited U24230HR2019PTC084079
Director10 Dec 20192019Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 May 20132013Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Farlex Lifesciences Private Limited
Oxermed Labs Private Limited
Farlex Pharmaceuticals Private Limited
Krishna Intercontinental Private Limited
Premium access

Shareholding and investment profile for Saurabh Juneja

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Saurabh Juneja

Saurabh Juneja currently holds 5 directorships: Farlex Pharmaceuticals Private Limited (Director, since 09 Nov 2019, revenue ₹15.67 Cr (FY 2025)); Kesar Drugs Private Limited (Director, since 10 Oct 2022, revenue ₹70.9 Lakh (FY 2025)); Oxermed Labs Private Limited (Director, since 03 May 2021, revenue ₹42.7 Lakh (FY 2024)); Kesar Aerosols Private Limited (Director, since 25 Aug 2026); Farlex Lifesciences Private Limited (Director, since 10 Dec 2019).

Saurabh Juneja was first appointed on 30 May 2013 as Director at Krishna Intercontinental Private Limited. The most recent appointment on record is 25 Aug 2026 at Kesar Aerosols Private Limited.

The 3 current companies of Saurabh Juneja that report revenue have a combined latest revenue of ₹16.81 Cr: Farlex Pharmaceuticals Private Limited ₹15.67 Cr (FY 2025); Kesar Drugs Private Limited ₹70.9 Lakh (FY 2025); Oxermed Labs Private Limited ₹42.7 Lakh (FY 2024).

Saurabh Juneja held 1 earlier board appointment: Krishna Intercontinental Private Limited (Director, from 30 May 2013).

The current boards of Saurabh Juneja's companies include Aarti (Farlex Pharmaceuticals Private Limited), Sajjan Kumar (Kesar Drugs Private Limited), Balinder Kumar (Oxermed Labs Private Limited), Harishender Mohan (Oxermed Labs Private Limited), Ashok Kumar (Kesar Aerosols Private Limited), Kunal Garg (Kesar Aerosols Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available